Acta Scientific Pharmacology

Review Article Volume 1 Issue 9

Novel Coronavirus: A Newly Arranged Review

Siwani Devi1*, Kishan Tripathi1, Mohammad Mukim1,2, Vidhi Jain1 and Rahul Kumar Ancheria1

1Kota College of Pharmacy, Kota, Rajasthan, India
2Dr. A.P.J Abdul Kalam University, Indore, MP, India

*Corresponding Author:Siwani Devi, Kota College of Pharmacy, Kota, Rajasthan, India.

Received: May 05, 2020; Published: August 12, 2020

×

Abstract

Coronavirus infect many of animals, including humans beings and rarely can be transmitted from animals to humans and then from one person to large population. The Official name of the Coronavirus is COVID-19. This coronavirus infection have great concern in global. It is first time reported in the China (Wuhan), in end of December 2019 From China it has spread too many other countries around the world at very faster rate. Now India is also one of Organization) declared Novel Coronavirus a “Pandemic”. From China it is spreader from seafood and meat. Major symptoms of this infection is respiratory illness. The people which can get easily infected by Coronavirus are Old people (age above 60 years), children (age below 10 Years), Pregnant women and the people who are suffering from diseases like diabetes, cancer, cardiovascular diseases and any chronic respiratory diseases. This virus directly acts on the Immune system of the person. This disease is transmitted by inhalation or contact with droplets and the incubation period ranges from 2 to 14 days. When healthy one come in contact with saliva droplets or nose discharge of the infected shaking and wash every edible things before having it, use alcohol sanitizer to wash your hands. Till now there is no specific vaccines for this infection but by above precautions it can be controlled. In this review we will conclude detailed information of the coronavirus infection.

Keywords: China; COVID-19; Immune System; Precaution; Virus

×

References

  1. Tyrrell DAJ and Myint SH. “Medical microbiology”. (4th Edition) Galveston (TX) University of Texas Medical Branch at Galveston: (1996): 60.
  2. Chan JF., et al. “A novel coronavirus genome identified in a cluster of pneumonia cases – Wuhan, China”. CDC Weekly 2 (2020): 61-62.
  3. Woo PC., et al. “Coronavirus genomics and bioinformatics analysis”. Viruses 2 (2010): 1804-1820.
  4. Peiris J., et al. “Severe acute respiratory syndrome”. Nature Medicine12 (2004): S88-97.
  5. Rahman A and Sarkar A. “Risk factors for fatal middle east respiratory syndrome coronavirus infection in Saudi Arabia”. Journal of Public Health9 (2019) :1288-1293.
  6. International Committee on Taxonomy of Viruses (ICTV). Archived from the original 5. (2019): 14.
  7. Yin y., et al. “SARS and other coronavirus as causes of pneumonia”. Respirology 2 (2018): 130-137.
  8. Cascella M., et al. “Features, Evaluation and Treatment of Coronavirus (COVID-19)”. StatPearls Publishing, Treasure Island, FL (2020): 243.
  9. Muhammad A., et al. “COVID-19 infection: Origin, transmission, and characteristics of human Coronaviruses”. Journal of Advanced Research 24 (2020): 91–98.
  10. Huang P., et al. “Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspension”. Radiology (2020): 326.
  11. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 497-506.
  12. Luk HK., et al. “Evolution and phylogeny of SARS coronavirus, Infection, genetics and Evolution”. Molecular Epidemiology (2019): 21-30.
  13. Armstrong J., et al. “Sequence and topology of a model intracellular membrane protein E1 glycoprotein from a coronavirus”. Nature591 (1984): 751-752.
  14. Zhao Z., et al. “Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou China”. Journal of Medical Microbiology 52 (2003): 715-720.
  15. Chan JF., et al. “Broad spectrum antivirals for the emerging Middle east respiratory syndrome coronavirus”. Journal of Information Security 67 (2013): 606-616.
  16. Al-Tawif JA., et al. “Ribavirin and interferon therapy in patients infected with the Middle east respiratory syndrome coronavirus: an observational study”. International Journal of Infectious Diseases 20 (2014): 40-46.
  17. Al-Qahanti AA., et al. “Middle east respiratory syndrome coronavirus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARy”. Oncotarget 6 (2017): 9053-9066.
  18. Arabi YM., et al. “Middle east respiratory syndrome”. The New England Journal of Medicine 6 (2017): 584-594.
  19. Nal B., et al. “Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins”. The Journal of General Virology5 (2005): 423-434.
  20. Armstrong J., et al. “Sequence and topology of a model intracellular membrane protein E1 glycoprotein in from a coronavirus”. Nature 308 (1984): 751-752.
  21. De Groot RJ., et al. “Evidence for a coiled-coil structure in the spike proteins of coronavirus”. Journal of Molecular Biology 4 (1987): 963-966.
  22. International committee on Taxonomy of virus (ITCV). Archived from the original (2018): 4.
  23. Decaro N., et al. “Gammacoronavirus”. Springer (2019): 403-413.
  24. Galler C., et al. “Human coronavirus insights into environmental resistance and its influence on the development of new antiseptics strategies”. Virus 11 (2012): 3044-3068.
×

Citation

Citation: Siwani Devi., et al. “Novel Coronavirus: A Newly Arranged Review".Acta Scientific Pharmacology 1.9 (2020): 16-20.




Metrics

Acceptance rate36%
Acceptance to publication20-30 days

Indexed In


News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"

Contact US